| Dr Evelyn Junko Nakagawa, MD | |
|
2800 Benedict Dr, San Leandro, CA 94577-6840 | |
| (415) 233-3604 | |
| (415) 295-5109 |
| Full Name | Dr Evelyn Junko Nakagawa |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 32 Years |
| Location | 2800 Benedict Dr, San Leandro, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023077294 | NPI | - | NPPES |
| 00A687250 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | A68752 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Empres Post Acute Rehabilitation | Petaluma, CA | Nursing home |
| South Marin Health & Wellness Center | Greenbrae, CA | Nursing home |
| Smith Ranch Skilled Nursing & Rehabilitation Cente | San rafael, CA | Nursing home |
| The Redwoods, A Community Of Seniors | Mill valley, CA | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Evelyn J Nakagawa Md Inc | 2466846399 | 2 |
News Archive
Implementing a centralized network that links province-wide pharmacy and hospital data could reduce the number of inappropriate filled prescriptions, show Canadian study results.
Development agencies in Ghana must join efforts to eradicate malaria in the country by 2015, Kwabena Osei Bonsu, leader of the nongovernmental organization Add Your Voice Now, said Sunday, GNA/Modern Ghana News reports.
Raptor Pharmaceutical Corp., today announced results from a Phase 2b clinical trial of its proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis"). The trial, conducted at the University of California, San Diego ("UCSD") General Clinical Research Center, evaluated safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of DR Cysteamine in nine cystinosis patients.
For workers in human service settings, job factors like role conflicts and high emotional demands can increase the risk of burnout—leading to long-term sickness absence, reports a study in the September Journal of Occupational and Environmental Medicine, official publication of the American College of Occupational and Environmental Medicine (ACOEM).
› Verified 2 days ago
| Entity Name | Quantum Healthcare Medical Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568490597 PECOS PAC ID: 5294647574 Enrollment ID: O20040924000422 |
News Archive
Implementing a centralized network that links province-wide pharmacy and hospital data could reduce the number of inappropriate filled prescriptions, show Canadian study results.
Development agencies in Ghana must join efforts to eradicate malaria in the country by 2015, Kwabena Osei Bonsu, leader of the nongovernmental organization Add Your Voice Now, said Sunday, GNA/Modern Ghana News reports.
Raptor Pharmaceutical Corp., today announced results from a Phase 2b clinical trial of its proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis"). The trial, conducted at the University of California, San Diego ("UCSD") General Clinical Research Center, evaluated safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of DR Cysteamine in nine cystinosis patients.
For workers in human service settings, job factors like role conflicts and high emotional demands can increase the risk of burnout—leading to long-term sickness absence, reports a study in the September Journal of Occupational and Environmental Medicine, official publication of the American College of Occupational and Environmental Medicine (ACOEM).
› Verified 2 days ago
| Entity Name | Inpatient Consultants Of California Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831134253 PECOS PAC ID: 7618861501 Enrollment ID: O20050318000829 |
News Archive
Implementing a centralized network that links province-wide pharmacy and hospital data could reduce the number of inappropriate filled prescriptions, show Canadian study results.
Development agencies in Ghana must join efforts to eradicate malaria in the country by 2015, Kwabena Osei Bonsu, leader of the nongovernmental organization Add Your Voice Now, said Sunday, GNA/Modern Ghana News reports.
Raptor Pharmaceutical Corp., today announced results from a Phase 2b clinical trial of its proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis"). The trial, conducted at the University of California, San Diego ("UCSD") General Clinical Research Center, evaluated safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of DR Cysteamine in nine cystinosis patients.
For workers in human service settings, job factors like role conflicts and high emotional demands can increase the risk of burnout—leading to long-term sickness absence, reports a study in the September Journal of Occupational and Environmental Medicine, official publication of the American College of Occupational and Environmental Medicine (ACOEM).
› Verified 2 days ago
| Entity Name | Knd Development 59 Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740519081 PECOS PAC ID: 3678602802 Enrollment ID: O20100724000249 |
News Archive
Implementing a centralized network that links province-wide pharmacy and hospital data could reduce the number of inappropriate filled prescriptions, show Canadian study results.
Development agencies in Ghana must join efforts to eradicate malaria in the country by 2015, Kwabena Osei Bonsu, leader of the nongovernmental organization Add Your Voice Now, said Sunday, GNA/Modern Ghana News reports.
Raptor Pharmaceutical Corp., today announced results from a Phase 2b clinical trial of its proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis"). The trial, conducted at the University of California, San Diego ("UCSD") General Clinical Research Center, evaluated safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of DR Cysteamine in nine cystinosis patients.
For workers in human service settings, job factors like role conflicts and high emotional demands can increase the risk of burnout—leading to long-term sickness absence, reports a study in the September Journal of Occupational and Environmental Medicine, official publication of the American College of Occupational and Environmental Medicine (ACOEM).
› Verified 2 days ago
| Entity Name | Ca Pacs 2 Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801372669 PECOS PAC ID: 4981954476 Enrollment ID: O20180904002122 |
News Archive
Implementing a centralized network that links province-wide pharmacy and hospital data could reduce the number of inappropriate filled prescriptions, show Canadian study results.
Development agencies in Ghana must join efforts to eradicate malaria in the country by 2015, Kwabena Osei Bonsu, leader of the nongovernmental organization Add Your Voice Now, said Sunday, GNA/Modern Ghana News reports.
Raptor Pharmaceutical Corp., today announced results from a Phase 2b clinical trial of its proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis"). The trial, conducted at the University of California, San Diego ("UCSD") General Clinical Research Center, evaluated safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of DR Cysteamine in nine cystinosis patients.
For workers in human service settings, job factors like role conflicts and high emotional demands can increase the risk of burnout—leading to long-term sickness absence, reports a study in the September Journal of Occupational and Environmental Medicine, official publication of the American College of Occupational and Environmental Medicine (ACOEM).
› Verified 2 days ago
| Entity Name | Evelyn J Nakagawa Md Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003577305 PECOS PAC ID: 2466846399 Enrollment ID: O20220218000896 |
News Archive
Implementing a centralized network that links province-wide pharmacy and hospital data could reduce the number of inappropriate filled prescriptions, show Canadian study results.
Development agencies in Ghana must join efforts to eradicate malaria in the country by 2015, Kwabena Osei Bonsu, leader of the nongovernmental organization Add Your Voice Now, said Sunday, GNA/Modern Ghana News reports.
Raptor Pharmaceutical Corp., today announced results from a Phase 2b clinical trial of its proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis"). The trial, conducted at the University of California, San Diego ("UCSD") General Clinical Research Center, evaluated safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of DR Cysteamine in nine cystinosis patients.
For workers in human service settings, job factors like role conflicts and high emotional demands can increase the risk of burnout—leading to long-term sickness absence, reports a study in the September Journal of Occupational and Environmental Medicine, official publication of the American College of Occupational and Environmental Medicine (ACOEM).
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Evelyn Junko Nakagawa, MD 14 Tamal Vista Blvd, Corte Madera, CA 94925-1107 Ph: (415) 233-3604 | Dr Evelyn Junko Nakagawa, MD 2800 Benedict Dr, San Leandro, CA 94577-6840 Ph: (415) 233-3604 |
News Archive
Implementing a centralized network that links province-wide pharmacy and hospital data could reduce the number of inappropriate filled prescriptions, show Canadian study results.
Development agencies in Ghana must join efforts to eradicate malaria in the country by 2015, Kwabena Osei Bonsu, leader of the nongovernmental organization Add Your Voice Now, said Sunday, GNA/Modern Ghana News reports.
Raptor Pharmaceutical Corp., today announced results from a Phase 2b clinical trial of its proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis"). The trial, conducted at the University of California, San Diego ("UCSD") General Clinical Research Center, evaluated safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of DR Cysteamine in nine cystinosis patients.
For workers in human service settings, job factors like role conflicts and high emotional demands can increase the risk of burnout—leading to long-term sickness absence, reports a study in the September Journal of Occupational and Environmental Medicine, official publication of the American College of Occupational and Environmental Medicine (ACOEM).
› Verified 2 days ago
Jeffrey Silvers, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 13847 E 14th St, Suite 116, San Leandro, CA 94578 Phone: 510-895-0388 Fax: 510-895-0342 | |
Dr. Asaf Shor, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2500 Merced St, San Leandro, CA 94577 Phone: 510-454-1000 | |
Dr. Arlen Randall Hoh, MD, MPH Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 15400 Foothill Blvd, San Leandro, CA 94578 Phone: 510-895-4288 Fax: 510-895-4285 | |
Masood Younus, Internal Medicine Medicare: Medicare Enrolled Practice Location: 2500 Merced St Bldg A1, San Leandro, CA 94577 Phone: 510-454-2434 | |
Tri Dang Do, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 101 Callan Ave Ste 300, San Leandro, CA 94577 Phone: 510-300-5340 | |
Dr. Shraddha Prakash, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2500 Merced St, Kaiser Permanente, San Leandro, CA 94577 Phone: 510-454-5750 |